The Complete Guide to Growth-Hormone Peptides

TL;DR

• Two families, one map - GHRH analogs trigger the GH pulse; ghrelin mimetics amplify it.
• They're paired because the receptors differ - a GHRH analog plus a GHRP produces a synergistic release greater than either alone.
• Only tesamorelin is FDA-approved, for HIV-associated lipodystrophy; everything else here is off-label, compounded or research-grade.
• Ipamorelin is the selective one - it lifts GH without dragging up cortisol or prolactin.
• MK-677 carries the clearest safety signals - an oral non-peptide with human data out to two years, and documented concerns alongside it.
• Raising IGF-1 is not free - a cancer-history screening question, plus real effects on insulin sensitivity and blood sugar.

The "GH peptides" are marketed as interchangeable muscle boosters. They aren't. Almost all of them make sense the moment you see the one thing they have in common - the growth-hormone → IGF-1 axis - and which knob each one turns. This guide is the map: what each compound does, which has real evidence, how they're paired, and where the honest risks are.

Educational content, not medical advice. No doses or protocols appear; GH-axis use is physician-directed. Most compounds here are not FDA-approved for muscle, anti-aging, or fat-loss use.

---

Growth-hormone peptides are the most misunderstood corner of the peptide world - a pile of similar-sounding names (sermorelin, ipamorelin, CJC-1295, tesamorelin, MK-677) sold as if they were the same "muscle peptide." They're not. They split into a few clean categories based on how they raise growth hormone, and once you see that split, the whole category organizes itself - and the genuinely risky options become easy to spot. This guide maps the field and routes you to the honest deep-dive on each.

What this guide covers

Start with the science

• How growth-hormone peptides actually work - the GH/IGF-1 axis
• What an IGF-1 level actually shows - why the axis is judged on this marker, and what a moving number does and doesn't prove

The compounds

• Sermorelin: the original GHRH analogue
• Ipamorelin - the selective, "clean" ghrelin mimetic
• CJC-1295 (with or without DAC) - the long-acting GHRH analog
• CJC-1295 + ipamorelin - why the classic pairing is paired, and what the evidence supports
• Tesamorelin - the one FDA-approved GHRH analog
• MK-677 (ibutamoren) - the oral, non-peptide secretagogue
• GHRP-2, GHRP-6 and hexarelin - the first-generation secretagogues and why the field moved on

Choosing

• Sermorelin vs CJC-1295 vs tesamorelin - how to choose a GHRH analog
• Recombinant GH versus secretagogues, head to head - replacing the hormone versus asking the gland to release it
• GH peptides and TRT are not the same decision - two separate endocrine axes, with different indications, monitoring and reversibility
• Testosterone vs GH peptides for muscle and recomposition - what each moves (muscle, fat, connective tissue) and why people pair them

Access & safety

• Growth hormone and cancer risk: what the observational data shows - the IGF-1 rationale, what the epidemiology reports, and why replacement in deficiency is not the same exposure as elevation in a normal axis
• PEG-MGF: the fifth name on the next FDA docket - what pegylated mechano growth factor is, why it has no human evidence base, and what a compounding-docket nomination does and does not mean

Related

• Peptides for sleep · Peptide side effects, honestly

The two families (this is the whole map)

Every GH-axis compound does one of two things - trigger the pulse or amplify it:

• GHRH analogs ("pulse trigger"). Sermorelin, CJC-1295 and tesamorelin bind the GHRH receptor and mimic the hypothalamic signal that initiates each natural GH pulse. They differ mainly in how long they last.
• Ghrelin mimetics / GHRPs ("pulse amplifier"). Ipamorelin (a peptide) and MK-677 (an oral small molecule) act on a different receptor to boost the size of the pulse. Ipamorelin is prized for being selective - it lifts GH without dragging up cortisol or prolactin.

The reason the two get combined is mechanical: because they hit separate receptor systems, a GHRH analog plus a GHRP produces a synergistic GH release greater than either alone. That's the logic behind the classic CJC-1295 + ipamorelin pairing - though the mechanistic case for it runs well ahead of the human trial evidence.

Master quick-reference

The honest risk frame

Raising GH/IGF-1 is not free. The shared cautions across this whole class: IGF-1 elevation carries a theoretical concern anywhere cell proliferation matters (a cancer-history screening question), GH secretagogues can affect insulin sensitivity and blood sugar (most pronounced with MK-677), and most of these are sold "for research use only" with unverified purity. This is a class that belongs in supervised care with baseline and follow-up bloodwork - not a self-directed grey-market stack. The specifics live in each spoke.

FAQ

What are growth-hormone peptides? Compounds that raise your own GH output - either by triggering the pulse (GHRH analogs like sermorelin, CJC-1295, tesamorelin) or amplifying it (ghrelin mimetics like ipamorelin, and the oral MK-677). Only tesamorelin is FDA-approved, for one specific condition.

Which growth-hormone peptide is best? There's no single "best" - it depends on the goal and the evidence bar. Tesamorelin has the strongest data; ipamorelin is the cleanest secretagogue; CJC-1295 + ipamorelin is the common pairing. Compare the GHRH analogs here.

Are they safe? They share GH/IGF-1 and blood-sugar cautions and need screening and monitoring; MK-677 carries the clearest safety signals. Supervised use with verified product is the only sensible route.

---

Considering GH-axis support? Vivre Labs approaches it as one system - matching the compound to your goals and labs, with baseline and follow-up bloodwork and honest evidence-tiering. Book a consult to understand your options. vivrelabs.com - Telegram · explore the V-G1 Build GH-axis protocol.

Educational content, not medical advice. GH-axis compounds raise GH/IGF-1 and can affect insulin sensitivity; use is physician-directed with monitoring. Most named compounds are not FDA-approved for these uses. SEA-market claims are subject to MAB requirements.